DCM
ALXN

Driehaus Capital Management’s Alexion Pharmaceuticals ALXN Stock Holding History

Driehaus Capital Management’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-92,205
Closed -$16.9M – 524
2021
Q2 		$16.9M Buy
92,205
+4,500
+5% +$772K 0.22% 146
2021
Q1 		$13.4M Buy
+87,705
New +$13.6M 0.2% 158
2019
Q3 		– Sell
-1,565
Closed -$205K – 604
2019
Q2 		$205K Buy
+1,565
New +$202K 0.01% 452
2013
Q3 		– Sell
-26,576
Closed -$2.45M – 537
2013
Q2 		$2.45M Buy
+26,576
New +$2.56M 0.11% 235

Other funds holding ALXN

BCI
Brinker Capital Investments Berwyn, Pennsylvania $13.1B AUM 28.37% 1-Year Est. Return
NICM
Neo Ivy Capital Management New York $434M AUM 44.19% 1-Year Est. Return
TAIM
TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return
RG
Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return
CFO
CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.96B AUM 48.96% 1-Year Est. Return

Driehaus Capital Management's ALXN Position: Q3 2021 in Review

Driehaus Capital Management sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 92,205 shares — an estimated $16.9M sold.

Driehaus Capital Management first reported a position in ALXN in Q2 2013 and held it in 4 quarters. The position peaked at $16.9M in Q2 2021. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

  • Driehaus Capital Management reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Driehaus Capital Management sold 92,205 Alexion Pharmaceuticals shares in Q3 2021, an estimated $16.9M.
  • Driehaus Capital Management first reported a position in Alexion Pharmaceuticals in Q2 2013 and held it in 4 quarters.
  • Driehaus Capital Management's Alexion Pharmaceuticals position peaked at $16.9M in Q2 2021.
  • 7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Driehaus Capital Management's 13F filing for Q3 2021, filed 15 Nov 2021.